Delivery Order SPE2DR25D9127-SPE2DR26FCZD9
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/mL. The award, issued on January 5, 2026, with an ultimate completion date of January 6, 2026, utilizes firm fixed-price pricing with no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group...
- The Defense Logistics Agency (DLA) awarded a $39,900 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Fasenra 30 mg/mL syringes. The award, issued on December 17, 2025, with a completion date of December 18, 2025, represents a firm fixed-price delivery order with no set-aside designation. This contract leverages DMS Pharmaceutical Group's position as a regional prime vendor under the DLA's Pharmaceutical...
- The Defense Logistics Agency has awarded a delivery order valued at $9,774.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of FASENRA 30 mg/ml syringes. DMS Pharmaceutical Group Inc. is a critical supplier within the federal pharmaceutical supply chain and has been registered in the System for Award Management since 2001. This delivery order was issued without a set-aside designation, reflecting the...
- The Defense Logistics Agency issued a delivery order valued at $14,962.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of FASENRA PEN 30 MG/ML. This firm fixed-price delivery order, awarded on January 5, 2026, with an ultimate completion date of January 6, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $7,330.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the provision of Fasenra 30 mg/ml syringes, and is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group valued at up to $499,999,999 that runs through December 31, 2025. This IDC, under the SPE2DB program, allows the DLA to issue...
- The Defense Logistics Agency (DLA) awarded a $14,962.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Fasenra 30 mg/ml syringes. The award, issued on December 2, 2025, with an ultimate completion date of December 3, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group was selected as...
- The Defense Logistics Agency issued a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of FASENRA Pen 30 mg/ml. This firm fixed-price delivery order, awarded on January 5, 2026, represents the final completion date of January 6, 2026, and was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $4,887.00, is for the supply of FASENRA PEN 30 MG/MLML, a pharmaceutical product. This delivery order is under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group that has a ceiling value of up to $499,999,999 and runs through December 31, 2025. The IDC allows DLA to...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $24,435 to DMS Pharmaceutical Group Inc. for Fasenra 30 mg/ml syringes. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order is scheduled for completion by November 3, 2025, and represents one of numerous...
- The Defense Logistics Agency awarded a $24,937.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra 30 mg/mL syringes. The delivery order, issued on November 24, 2025, with an ultimate completion date of November 25, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award falls under...
- SPE2DR25D9127Indefinite Delivery Contract
- SPE2DR25D9127-SPE2DR26FCZD9Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/mL. The contract is a firm fixed-price delivery order with an ultimate completion date of January 7, 2026, and was issued without a set-aside designation. DMS Pharmaceutical Group is performing work at its headquarters location in Park Ridge, Illinois. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA, awarded on November 13, 2025, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. That master contract carries a $499.999 billion ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a critical supplier of branded and generic pharmaceuticals, biologics, vaccines, and medical consumables to support Department of Defense military healthcare facilities worldwide. The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to optimize the federal military medical supply chain, and this delivery order exemplifies the recurring pharmaceutical procurement executed under that framework to meet ongoing DoD healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 1/5/26 |